chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 70.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Fatigue, Headache, Malaise, Myalgia
Clinical narrative: tiredness; nausea; feeling unwell; Site pain; headache; muscle pain; chills; This is a spontaneous report from a contactable consumer, the patient. A 70-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; lot number: ER8733), via an unspecified route of administration in the left arm on 25Mar2021 at 12:30 (at the age of 70-years-old), as a single dose for COVID -19 immunisation. Medical history included high blood pressure. The patient did not have any allergies to medications, food, or other products. Concomitant medications included metoprolol (MANUFACTURER UNKNOWN) and lisinopril (MANUFACTURER UNKNOWN) for unknown indications from unknown date. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; lot number: EN6204), via an unspecified route of administration in the left arm on 04Mar2021 at 12:30 (at the age of 70-years-old), as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 26Mar2021, after 1 day of vaccination, the patient experienced site pain, tiredness, headache, muscle pain, chills, nausea and feeling unwell. The patient did not receive any treatment for the reported events. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of site pain, tiredness, headache, muscle pain, chills, nausea and feeling unwell was not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 70.0
Sex: F
Vaccine: COVID19
Symptoms: Nausea, Vaccination site pain
Clinical narrative: tiredness; nausea; feeling unwell; Site pain; headache; muscle pain; chills; This is a spontaneous report from a contactable consumer, the patient. A 70-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; lot number: ER8733), via an unspecified route of administration in the left arm on 25Mar2021 at 12:30 (at the age of 70-years-old), as a single dose for COVID -19 immunisation. Medical history included high blood pressure. The patient did not have any allergies to medications, food, or other products. Concomitant medications included metoprolol (MANUFACTURER UNKNOWN) and lisinopril (MANUFACTURER UNKNOWN) for unknown indications from unknown date. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; lot number: EN6204), via an unspecified route of administration in the left arm on 04Mar2021 at 12:30 (at the age of 70-years-old), as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 26Mar2021, after 1 day of vaccination, the patient experienced site pain, tiredness, headache, muscle pain, chills, nausea and feeling unwell. The patient did not receive any treatment for the reported events. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of site pain, tiredness, headache, muscle pain, chills, nausea and feeling unwell was not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 39.0
Sex: F
Vaccine: COVID19
Symptoms: Blood pressure measurement, Chills, Decreased appetite, Depressed mood, Dizziness
Clinical narrative: heart was pounding; skin became blotchy all over; tongue was tingling; blood pressure it was 186/123; excessive thirst; light-headedness; metal/chemical taste; extremely jittery; on edge feeling; loss of apatite; chills; fever; breathing was labored; This is a spontaneous report from a contactable consumer, the patient. A 39-years-old non-pregnant female patient received first dose of BNT162b2 (PFIZER BIONTECH COVID-19 mRNA VACCINE, Lot number: ER 8732), via an unspecified route of administration in left arm on 26Mar2021 at 13:30 (at the age of 39-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma. Concomitant medications included loratadine (CLARITIN) for unknown indication. Prior to vaccination, the patient was diagnosed with COVID-19. The patient was allergic to penicillin. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 24Mar2021, within five minutes of vaccination, the patient experienced heart pounding, skin became blotchy all over, tingling tongue, and when the technician had a check her blood pressure was found to be186/123 (her blood pressure was usually 117/over 70). The patient went to an urgent care and the doctor told, it appeared to be an allergic reaction (though not anaphylactic shock) to the vaccine and advised not to receive the second dose. The other symptoms included were excessive thirst, light-headedness, metal/ chemical taste in her mouth, extremely jittery and on edge feeling, loss of appetite, chills and fever. The following day the patient experienced laboured breathing from lightly walking around (not usual for the patient). The patient did not receive any treatment for adverse events. The clinical outcome of the events heart pounding, blotchy skin all over, tingling tongue, hypertension, excessive thirst, light headedness, taste metallic, jitteriness, depressed mood, loss of appetite, chills and fever was resolved with sequelae on an unknown date in Mar2021.   No follow-up attempts are needed. No further information is expected.
Age: 39.0
Sex: F
Vaccine: COVID19
Symptoms: Dysgeusia, Dyspnoea, Feeling jittery, Hypertension, Palpitations
Clinical narrative: heart was pounding; skin became blotchy all over; tongue was tingling; blood pressure it was 186/123; excessive thirst; light-headedness; metal/chemical taste; extremely jittery; on edge feeling; loss of apatite; chills; fever; breathing was labored; This is a spontaneous report from a contactable consumer, the patient. A 39-years-old non-pregnant female patient received first dose of BNT162b2 (PFIZER BIONTECH COVID-19 mRNA VACCINE, Lot number: ER 8732), via an unspecified route of administration in left arm on 26Mar2021 at 13:30 (at the age of 39-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma. Concomitant medications included loratadine (CLARITIN) for unknown indication. Prior to vaccination, the patient was diagnosed with COVID-19. The patient was allergic to penicillin. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 24Mar2021, within five minutes of vaccination, the patient experienced heart pounding, skin became blotchy all over, tingling tongue, and when the technician had a check her blood pressure was found to be186/123 (her blood pressure was usually 117/over 70). The patient went to an urgent care and the doctor told, it appeared to be an allergic reaction (though not anaphylactic shock) to the vaccine and advised not to receive the second dose. The other symptoms included were excessive thirst, light-headedness, metal/ chemical taste in her mouth, extremely jittery and on edge feeling, loss of appetite, chills and fever. The following day the patient experienced laboured breathing from lightly walking around (not usual for the patient). The patient did not receive any treatment for adverse events. The clinical outcome of the events heart pounding, blotchy skin all over, tingling tongue, hypertension, excessive thirst, light headedness, taste metallic, jitteriness, depressed mood, loss of appetite, chills and fever was resolved with sequelae on an unknown date in Mar2021.   No follow-up attempts are needed. No further information is expected.
Age: 39.0
Sex: F
Vaccine: COVID19
Symptoms: Paraesthesia oral, Pyrexia, Rash macular, Thirst
Clinical narrative: heart was pounding; skin became blotchy all over; tongue was tingling; blood pressure it was 186/123; excessive thirst; light-headedness; metal/chemical taste; extremely jittery; on edge feeling; loss of apatite; chills; fever; breathing was labored; This is a spontaneous report from a contactable consumer, the patient. A 39-years-old non-pregnant female patient received first dose of BNT162b2 (PFIZER BIONTECH COVID-19 mRNA VACCINE, Lot number: ER 8732), via an unspecified route of administration in left arm on 26Mar2021 at 13:30 (at the age of 39-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma. Concomitant medications included loratadine (CLARITIN) for unknown indication. Prior to vaccination, the patient was diagnosed with COVID-19. The patient was allergic to penicillin. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 24Mar2021, within five minutes of vaccination, the patient experienced heart pounding, skin became blotchy all over, tingling tongue, and when the technician had a check her blood pressure was found to be186/123 (her blood pressure was usually 117/over 70). The patient went to an urgent care and the doctor told, it appeared to be an allergic reaction (though not anaphylactic shock) to the vaccine and advised not to receive the second dose. The other symptoms included were excessive thirst, light-headedness, metal/ chemical taste in her mouth, extremely jittery and on edge feeling, loss of appetite, chills and fever. The following day the patient experienced laboured breathing from lightly walking around (not usual for the patient). The patient did not receive any treatment for adverse events. The clinical outcome of the events heart pounding, blotchy skin all over, tingling tongue, hypertension, excessive thirst, light headedness, taste metallic, jitteriness, depressed mood, loss of appetite, chills and fever was resolved with sequelae on an unknown date in Mar2021.   No follow-up attempts are needed. No further information is expected.
Age: 21.0
Sex: F
Vaccine: COVID19
Symptoms: Hypertrophy of tongue papillae
Clinical narrative: Swollen sores and inflamed tastebudsall over my tongue; This is a spontaneous report from a contactable consumer, the patient. A 21-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN), via an unspecified route of administration in the right arm on 26Mar2021 at 15:15 (at the age of 21-years-old), as a single dose for COVID-19 immunisation. Medical history included COVID-19, which was diagnosed prior to vaccination. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient did not receive any other medications within 2 weeks of vaccination. Since the vaccination, the patient had not been tested for COVID-19. On 27Mar2021, the patient experienced swollen sores and inflamed taste buds all over tongue. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. It was unknown if patient received treatment for the adverse event. The clinical outcome of the event swollen sores and inflamed taste buds all over tongue was unknown at the time of this report.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Blood pressure measurement, Chills, Disturbance in attention, Dizziness, Dysphagia
Clinical narrative: hives on my knees; light sensitivity; concentration difficult throughout experience; felt very dizzy; Knees swollen; neck discomfort; headache; area swollen from nose to chin; sore injection site,; fatigue; foggy during day; felt my heart beating hard within 5 minutes of vaccine; my lips were numb; I felt a little trouble swallowing.; Had chills; had swelling around lips/mouth; This is a spontaneous report received from a contactable consumer, the patient. A 60-year-old non pregnant female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot/batch no : ER8727) via an unspecified route of administration in the left arm on 24Mar2021 at 11:300 (at the age of 60-year-old), as a single dose for COVID-19 immunisation. The patient had no Medical history. Concomitant medications included with supplements. The patient previously received Sulpha Drugs on an unknown date for unspecified indication and experienced a  sulfonamide allergy. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 24Mar2021 at 11:00, the experienced heart beating hard within 5 minutes of vaccine and her lips were numb and she felt a little trouble swallowing, and had chills, and had swelling around lips/mouth. On 25Mar2021, the Patient experienced area swollen from nose to chin and Had headache, sore injection site, fatigue, foggy during day. On 26Mar2021, the patient experienced Fatigue and neck discomfort. On 27Mar2021, the patient experienced very dizzy, Knees swollen and Could not sleep on injection site. On 28Mar2021, the experienced hives on her knees, Light sensitivity and concentration difficult throughout experience.  The patient underwent lab tests and procedures, which included Blood pressure on unknown date and resulted normal. The patient called clinic for instructions and receive Benadryl for lips numbness, heart beating hard, trouble swallowing and chills. Patient had called doctor and awaited to call back. The clinical outcome of felt heart beating hard, numb lips, trouble swallowing, chills, area swollen from nose to chin, headache, fatigue, foggy during day, neck discomfort,  dizzy, swollen knees, hives on knees, light sensitivity and concentration difficult was not recovered and of the vaccination site pain was recovered on 26mar2021.   No follow-up attempts are possible. No further information is expected.
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Feeling abnormal, Headache, Hypoaesthesia oral, Joint swelling
Clinical narrative: hives on my knees; light sensitivity; concentration difficult throughout experience; felt very dizzy; Knees swollen; neck discomfort; headache; area swollen from nose to chin; sore injection site,; fatigue; foggy during day; felt my heart beating hard within 5 minutes of vaccine; my lips were numb; I felt a little trouble swallowing.; Had chills; had swelling around lips/mouth; This is a spontaneous report received from a contactable consumer, the patient. A 60-year-old non pregnant female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot/batch no : ER8727) via an unspecified route of administration in the left arm on 24Mar2021 at 11:300 (at the age of 60-year-old), as a single dose for COVID-19 immunisation. The patient had no Medical history. Concomitant medications included with supplements. The patient previously received Sulpha Drugs on an unknown date for unspecified indication and experienced a  sulfonamide allergy. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 24Mar2021 at 11:00, the experienced heart beating hard within 5 minutes of vaccine and her lips were numb and she felt a little trouble swallowing, and had chills, and had swelling around lips/mouth. On 25Mar2021, the Patient experienced area swollen from nose to chin and Had headache, sore injection site, fatigue, foggy during day. On 26Mar2021, the patient experienced Fatigue and neck discomfort. On 27Mar2021, the patient experienced very dizzy, Knees swollen and Could not sleep on injection site. On 28Mar2021, the experienced hives on her knees, Light sensitivity and concentration difficult throughout experience.  The patient underwent lab tests and procedures, which included Blood pressure on unknown date and resulted normal. The patient called clinic for instructions and receive Benadryl for lips numbness, heart beating hard, trouble swallowing and chills. Patient had called doctor and awaited to call back. The clinical outcome of felt heart beating hard, numb lips, trouble swallowing, chills, area swollen from nose to chin, headache, fatigue, foggy during day, neck discomfort,  dizzy, swollen knees, hives on knees, light sensitivity and concentration difficult was not recovered and of the vaccination site pain was recovered on 26mar2021.   No follow-up attempts are possible. No further information is expected.
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Lip swelling, Musculoskeletal discomfort, Palpitations, Photophobia, Swelling face
Clinical narrative: hives on my knees; light sensitivity; concentration difficult throughout experience; felt very dizzy; Knees swollen; neck discomfort; headache; area swollen from nose to chin; sore injection site,; fatigue; foggy during day; felt my heart beating hard within 5 minutes of vaccine; my lips were numb; I felt a little trouble swallowing.; Had chills; had swelling around lips/mouth; This is a spontaneous report received from a contactable consumer, the patient. A 60-year-old non pregnant female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot/batch no : ER8727) via an unspecified route of administration in the left arm on 24Mar2021 at 11:300 (at the age of 60-year-old), as a single dose for COVID-19 immunisation. The patient had no Medical history. Concomitant medications included with supplements. The patient previously received Sulpha Drugs on an unknown date for unspecified indication and experienced a  sulfonamide allergy. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 24Mar2021 at 11:00, the experienced heart beating hard within 5 minutes of vaccine and her lips were numb and she felt a little trouble swallowing, and had chills, and had swelling around lips/mouth. On 25Mar2021, the Patient experienced area swollen from nose to chin and Had headache, sore injection site, fatigue, foggy during day. On 26Mar2021, the patient experienced Fatigue and neck discomfort. On 27Mar2021, the patient experienced very dizzy, Knees swollen and Could not sleep on injection site. On 28Mar2021, the experienced hives on her knees, Light sensitivity and concentration difficult throughout experience.  The patient underwent lab tests and procedures, which included Blood pressure on unknown date and resulted normal. The patient called clinic for instructions and receive Benadryl for lips numbness, heart beating hard, trouble swallowing and chills. Patient had called doctor and awaited to call back. The clinical outcome of felt heart beating hard, numb lips, trouble swallowing, chills, area swollen from nose to chin, headache, fatigue, foggy during day, neck discomfort,  dizzy, swollen knees, hives on knees, light sensitivity and concentration difficult was not recovered and of the vaccination site pain was recovered on 26mar2021.   No follow-up attempts are possible. No further information is expected.
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Urticaria, Vaccination site pain
Clinical narrative: hives on my knees; light sensitivity; concentration difficult throughout experience; felt very dizzy; Knees swollen; neck discomfort; headache; area swollen from nose to chin; sore injection site,; fatigue; foggy during day; felt my heart beating hard within 5 minutes of vaccine; my lips were numb; I felt a little trouble swallowing.; Had chills; had swelling around lips/mouth; This is a spontaneous report received from a contactable consumer, the patient. A 60-year-old non pregnant female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot/batch no : ER8727) via an unspecified route of administration in the left arm on 24Mar2021 at 11:300 (at the age of 60-year-old), as a single dose for COVID-19 immunisation. The patient had no Medical history. Concomitant medications included with supplements. The patient previously received Sulpha Drugs on an unknown date for unspecified indication and experienced a  sulfonamide allergy. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 24Mar2021 at 11:00, the experienced heart beating hard within 5 minutes of vaccine and her lips were numb and she felt a little trouble swallowing, and had chills, and had swelling around lips/mouth. On 25Mar2021, the Patient experienced area swollen from nose to chin and Had headache, sore injection site, fatigue, foggy during day. On 26Mar2021, the patient experienced Fatigue and neck discomfort. On 27Mar2021, the patient experienced very dizzy, Knees swollen and Could not sleep on injection site. On 28Mar2021, the experienced hives on her knees, Light sensitivity and concentration difficult throughout experience.  The patient underwent lab tests and procedures, which included Blood pressure on unknown date and resulted normal. The patient called clinic for instructions and receive Benadryl for lips numbness, heart beating hard, trouble swallowing and chills. Patient had called doctor and awaited to call back. The clinical outcome of felt heart beating hard, numb lips, trouble swallowing, chills, area swollen from nose to chin, headache, fatigue, foggy during day, neck discomfort,  dizzy, swollen knees, hives on knees, light sensitivity and concentration difficult was not recovered and of the vaccination site pain was recovered on 26mar2021.   No follow-up attempts are possible. No further information is expected.
Age: 59.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Dizziness, Pyrexia, Vertigo
Clinical narrative: Dizziness; Feels like the room was spinning; Fever; This is a spontaneous report from a contactable nurse. A 59-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN), via intramuscular route of administration in the left arm on 18Mar2021 at 15:00 (at the age of 59-years-old), as a single dose for COVID-19 immunisation. Medical history was reported as COVID-19 on an unspecified date. The patient had no known allergies to medications, food or other products. The patient did not take any concomitant medications. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not tested for COVID-19.  On 19Mar2021 at 07:00, the patient experienced dizziness that felt like the room was spinning, and was having 100 degree fahrenheit . On 19Mar2021 at 07:00, the  body temperature was reported as 100 degree fahrenheit. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were taken as a result of events and included treatment with Tylenol, two tablets orally every six hours twice. The clinical outcome of the events dizziness, spinning sensation and was recovered on an unspecified date in Mar2021.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 26.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Diarrhoea, Hyperhidrosis, Nausea, Pyrexia
Clinical narrative: Fever; Nausea; Diarrhea; Vomiting; fever/sweats; Chills; Vertigo; This is a spontaneous report from a contactable consumer, the patient. A 26-years old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 27Mar2021 at 13:30 (at the age of 26-years-old) as a single dose for COVID-19 immunisation. Medical history included thalassemia, anaemia, bipolar 2 disorder. Concomitant medications included iron supplements (FLINSTONES VITAMINS). The patient did not have allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Post the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 27Mar2021 at 23:00, the patient experienced fever, nausea, diarrhea, vomiting, sweats, chills and vertigo. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive treatment for the reported events. The clinical outcome of the events fever, nausea, diarrhea, vomiting, sweating, chills and vertigo was recovering at the time of this report.   No follow-up attempts are needed; information about lot number cannot be obtained.
Age: 26.0
Sex: F
Vaccine: COVID19
Symptoms: Vertigo, Vomiting
Clinical narrative: Fever; Nausea; Diarrhea; Vomiting; fever/sweats; Chills; Vertigo; This is a spontaneous report from a contactable consumer, the patient. A 26-years old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the right arm on 27Mar2021 at 13:30 (at the age of 26-years-old) as a single dose for COVID-19 immunisation. Medical history included thalassemia, anaemia, bipolar 2 disorder. Concomitant medications included iron supplements (FLINSTONES VITAMINS). The patient did not have allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Post the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 27Mar2021 at 23:00, the patient experienced fever, nausea, diarrhea, vomiting, sweats, chills and vertigo. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive treatment for the reported events. The clinical outcome of the events fever, nausea, diarrhea, vomiting, sweating, chills and vertigo was recovering at the time of this report.   No follow-up attempts are needed; information about lot number cannot be obtained.
Age: 71.0
Sex: F
Vaccine: COVID19
Symptoms: Burning sensation, Dry eye, Dry skin, Eye pruritus, Eyelid exfoliation
Clinical narrative: Face and eyes became very dry and itchy; Face and eyes became very dry and itchy; Face and eyes became very dry and itchy; Face and eyes became very dry and itchy; Eyelids had scales like appearance; Whole face felt like on fire; Skin around eye area was also scaly; lots of phlegm; This is a spontaneous report received from a contactable consumer, the patient. A 71-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN) via an unspecified route of administration in the left arm on 26Feb2021 (at the age of 71-years-old) as a single dose for COVID-19 immunisation. Medical history included autoimmune diseases. The patient previously had no known allergies to food, medications, or other products. Concomitant medications included olmesartan (MANUFACTURER UNKNOWN), pregabalin (MANUFACTURER UNKNOWN), omeprazole (MANUFACTURER UNKNOWN) and hydroxychlo (MANUFACTURER UNKNOWN), all started on unknown dates for unknown indications. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: E19265) via an unspecified route of administration in the left arm on 05Feb2021 at 11:15 (at the age of 71-years-old), as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Since the vaccination, the patient had not been tested for COVID-19. On 08Mar2021 at 10:00, the patient experienced that the face and eyes became very dry and itchy. Eyelids had scales like appearance and lots of phlegm. The skin around eye area was also scaley. Whole face felt like it was on fire. The events resulted in dermatologist visit. It was reported that the patient was again calling doctor to have her eyes and eyesight reviewed as she had lots of pain and had planned to follow up with the dermatologist as well. Therapeutic measure taken as a result of the events experienced included hydrocortisone 2.5% cream (after three weeks the problem persisted for the reported events). The adverse events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive treatment for the adverse events. The clinical outcomes of the events face and eyes became very dry and itchy, eyelids had scales like appearance and lots of phlegm, skin around eye area was scaley and whole face felt like it was on fire were not resolved at the time of this report.    No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 71.0
Sex: F
Vaccine: COVID19
Symptoms: Productive cough, Pruritus, Skin exfoliation
Clinical narrative: Face and eyes became very dry and itchy; Face and eyes became very dry and itchy; Face and eyes became very dry and itchy; Face and eyes became very dry and itchy; Eyelids had scales like appearance; Whole face felt like on fire; Skin around eye area was also scaly; lots of phlegm; This is a spontaneous report received from a contactable consumer, the patient. A 71-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN) via an unspecified route of administration in the left arm on 26Feb2021 (at the age of 71-years-old) as a single dose for COVID-19 immunisation. Medical history included autoimmune diseases. The patient previously had no known allergies to food, medications, or other products. Concomitant medications included olmesartan (MANUFACTURER UNKNOWN), pregabalin (MANUFACTURER UNKNOWN), omeprazole (MANUFACTURER UNKNOWN) and hydroxychlo (MANUFACTURER UNKNOWN), all started on unknown dates for unknown indications. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: E19265) via an unspecified route of administration in the left arm on 05Feb2021 at 11:15 (at the age of 71-years-old), as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Since the vaccination, the patient had not been tested for COVID-19. On 08Mar2021 at 10:00, the patient experienced that the face and eyes became very dry and itchy. Eyelids had scales like appearance and lots of phlegm. The skin around eye area was also scaley. Whole face felt like it was on fire. The events resulted in dermatologist visit. It was reported that the patient was again calling doctor to have her eyes and eyesight reviewed as she had lots of pain and had planned to follow up with the dermatologist as well. Therapeutic measure taken as a result of the events experienced included hydrocortisone 2.5% cream (after three weeks the problem persisted for the reported events). The adverse events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive treatment for the adverse events. The clinical outcomes of the events face and eyes became very dry and itchy, eyelids had scales like appearance and lots of phlegm, skin around eye area was scaley and whole face felt like it was on fire were not resolved at the time of this report.    No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 32.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Diarrhoea, Nausea, Pain, Pyrexia
Clinical narrative: Fever 100.5; diarrhea; Nausea; severe pain; This is a spontaneous report from a contactable consumer, the patient. A 32-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8730) via an unspecified route of administration in the right arm on 25Mar2021 at 13:30 (at the age of 32-years-old) as a single dose for COVID-19 immunisation. Medical history includes neuropathy, chronic pain, Ehlers Danlos syndrome and postural orthostatic tachycardia syndrome (POTS). The patient had a history of allergy to Zanaflex and clindamycin. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. Concomitant medications were not reported. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 28Mar2021, the patient had experienced fever of 100.5 (unspecified units), nausea, diarrhoea and severe pain. Adverse events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events fever 100.5, nausea, diarrhoea and severe pain was not resolved at the time of this report. No follow-up attempts are needed. No further information is expected.
Age: 44.0
Sex: F
Vaccine: COVID19
Symptoms: Rash pruritic, Urticaria
Clinical narrative: Very itchy and irritated rash all over my body (including my face); Welts all over my body (including my face); This is a spontaneous report from a contactable consumer, the patient. A 44-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: ER2613) via an unspecified route of administration in the left arm on 19Mar2021 at 10:15 (at the age of 44-years-old), as a single dose for COVID-19 immunisation. Medical history included diabetes. Concomitant medication included insulin (MANUFACTURER UNKNOWN) for an unknown indication and from an unknown date. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: EN6201) via an unspecified route of administration in the left arm on 26Feb2021 at 10:15 (at the age of 44-years-old), as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not tested for COVID-19. On 23Mar2021 at 23:00, 2 to 3 days after the second dose of vaccination, the patient developed a rash and welts all over body including her face, that were irritating and very itchy. Therapeutic measures were taken as a result of welts and itchy rash and included treatment with diphenhydramine (BENADRYL) and ibuprofen both times when it happened. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcomes of the events rash and welts all over body including her face, that were irritating and very itchy were recovered on an unknown date in Mar2021.  No follow-up attempts are needed. No further information is expected.
Age: 46.0
Sex: M
Vaccine: COVID19
Symptoms: Back pain, Herpes zoster, Pain in extremity
Clinical narrative: Shingles; severe pain in back; severe pain in leg; This is a spontaneous report from a contactable consumer, the patient. A 47-year-old male patient received first dose of BNT162b2 (PFIZER BIONTECH COVID-19 mRNA Vaccine; Lot number: UNKNOWN), via an unspecified route of administration in left arm on 05Mar2021, 16:00 (at the age of 47-year-old) as a single dose for COVID-19 immunisation. The patient medical history was not reported. The patient had not received any other medications within 2 weeks of vaccination. The patient did not report any allergies to food or other medicinal products. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccination. On 21Mar2021, the patient experienced shingles, severe pain in back and leg. Therapeutic measures were taken as result of events reported and included treatment with anti-viral and pain medication (unspecified). The events resulted in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events shingles, severe pain in back and leg were resolving at the time of this report.   No follow up attempts are needed; information about lot/batch number cannot be obtained.
Age: 43.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Fatigue, Heart rate increased, Hypertension, Malaise
Clinical narrative: High blood pressure; high heart rate; chills; fever; site pain; body pain; tired; not feeling well; This is a spontaneous report from a contactable consumer, the patient. A 43-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: unknown), via an unspecified route of administration in the left arm on 27Mar2021 at 10:15 (at the age of 43-years-old), as a single dose for COVID-19 immunisation. Medical history included fibromyalgia, sleep apnea, hashimotos, Ehlers-Danlos syndrome (EDS). Concomitant medications were not reported. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: unknown), via an unspecified route of administration in the left arm on 06Mar2021 at 11:15 (at the age of 43-years-old), as a single dose for COVID-19 immunisation and mushroom and experience food allergy. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient was not tested for COVID-19. On 28Mar2021 at 00:00, the patient experienced high blood pressure, high heart rate, chills, fever, site pain (vaccination site pain), body pain, tired, and not feeling well. The patient did not receive treatment for the reported events. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events high blood pressure, high heart rate, chills, fever, vaccination site pain, general body pain, tiredness, and feeling unwell was not resolved.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 43.0
Sex: F
Vaccine: COVID19
Symptoms: Pain, Pyrexia, Vaccination site pain
Clinical narrative: High blood pressure; high heart rate; chills; fever; site pain; body pain; tired; not feeling well; This is a spontaneous report from a contactable consumer, the patient. A 43-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: unknown), via an unspecified route of administration in the left arm on 27Mar2021 at 10:15 (at the age of 43-years-old), as a single dose for COVID-19 immunisation. Medical history included fibromyalgia, sleep apnea, hashimotos, Ehlers-Danlos syndrome (EDS). Concomitant medications were not reported. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: unknown), via an unspecified route of administration in the left arm on 06Mar2021 at 11:15 (at the age of 43-years-old), as a single dose for COVID-19 immunisation and mushroom and experience food allergy. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient was not tested for COVID-19. On 28Mar2021 at 00:00, the patient experienced high blood pressure, high heart rate, chills, fever, site pain (vaccination site pain), body pain, tired, and not feeling well. The patient did not receive treatment for the reported events. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events high blood pressure, high heart rate, chills, fever, vaccination site pain, general body pain, tiredness, and feeling unwell was not resolved.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Sex: M
Vaccine: COVID19
Symptoms: Pain in extremity
Clinical narrative: Sore arm after injection; This is a spontaneous report received from a non-contactable consumer. A male patient of unknown age received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: unknown), via an unspecified route of administration on an unknown date for COVID-19 immunisation. Medical history and concomitant medication was not reported. On an unknown date, the patient experienced sore arm after injection. The clinical outcome of the event sore arm was unknown at the time of reporting. No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Sex: M
Vaccine: COVID19
Symptoms: Pain in extremity
Clinical narrative: Sore arm after injection; This is a spontaneous report from a non-contactable consumer. A male patient of unspecified age received unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: UNKNOWN), via an unspecified route of administration on an unspecified date as a single dose for COVID-19 immunisation. The patient's medical history and concomitant medications were not reported. On an unspecified date, the patient experienced sore arm after injection. The clinical outcome of the sore arm after injection was unknown.  No follow-up attempts are possible; information about lot number cannot be obtained.  Amendment: This follow-up report is being submitted to amend previously reported information.
Age: 70.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Pyrexia, Somnolence, Vaccination site pain
Clinical narrative: Injection site pain; low grade fever; Slight headache; Slept most of 36 hours straight; This is a spontaneous report from a contactable consumer, the patient. A 70-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8732), via an unspecified route of administration in the left arm on 25Mar2021 at 13:00 (at the age of 70-year-old) as a single dose for COVID-19 immunisation. Medical history included nasal allergy, asthma and gout. The patient was allergic to several antibiotics (unspecified). The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6199) via an unspecified route of administration in the left arm on 04Mar2021 at 13:00 as single dose for COVID-19 immunisation. Concomitant medications included multi vitamin (MANUFACTURER UNKNOWN), citalopram (MANUFACTURER UNKNOWN), oxybutynin chloride (MANUFACTURER UNKNOWN) and montelukast sodium (MONT), all for unknown indications and from unknown date.  Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 26Mar2021 at 4:00, the patient experienced injection site pain, low grade fever, slight headache. It was reported that she slept most of 36 hours straight. The patient did not receive any treatment for the reported events. The adverse events did not result in a visit to the doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of vaccination site pain, low grade fever, headache and sleepy was resolved on an unknown date in Mar2021.   No follow-up attempts are needed. No further information is expected.
Age: 71.0
Sex: M
Vaccine: COVID19
Symptoms: Chills, Headache, Oropharyngeal pain, Pyrexia, Rhinorrhoea
Clinical narrative: Headache; Chills; Temperatures; runny nose; sore throat; This is a spontaneous report from a contactable consumer, the patient. A 71-year-old male patient received unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: UNKNOWN), via unspecified route of administration in the left arm on 03Mar2021 at 15:30 (at the age of 71-years-old), as a single dose for COVID-19 immunisation. Medical history and allergies to medications, food, or other products was reported as yes. The patient received unspecified medications within 2 weeks of vaccination. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not tested for COVID-19. On 03Mar2021 at 21:00, the patient experienced headache, chills, temperatures, runny nose and sore throat. The patient did not receive any treatment for the events. The clinical outcome of the events headache, chills, temperatures, runny nose and sore throat was recovered on unknown date in Mar2021.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 46.0
Sex: M
Vaccine: COVID19
Symptoms: Dizziness, Headache, Nausea
Clinical narrative: Dizziness; Nausea; Headache; This is a spontaneous report from a contactable consumer, the patient. A 46-year-old male patient received the unknown dose of BNT162b2 (PFIZER BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN) via an unspecified route of administration in left arm on 26Mar2021 at 14:00 as single dose (at the age of 46 years) for COVID-19 immunisation. The medical history of the patient included high blood pressure. The patient had no known allergies. Concomitant medication was not reported. Prior to vaccination, the patient was not diagnosed with COVID-19; Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 27Mar2021 at 01:00, the patient experienced nausea, dizziness and headache. The patient did not receive any treatment for the reported events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event nausea, dizziness and headache was unknown at the time of report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.